SecBot SecBot

AMLX

Amylyx Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001658551 Biotech & Drug Discovery
$27.10 −0.10 (−0.37%)
Oct 26 4:00 PM ET · prev $27.20
Market cap
$3.6B
Mid cap
Consensus
Buy
89% Buy or better · 18 analysts
Median target
$42.00
+55% · range $20.00–57.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.37
1 year
+90.4%
from $14.23 · Oct 27
30 days
−9.2%
from $29.85
52-week range
$11.38–39.66
−32% from high · low Jan 6
Avg volume 20D
1.34M
shares / day
Short interest
12.67M
≈10.1% of shares · −6.3%
Days to cover
9.2
at average volume
Insider net
−$6.0M
1 buyer · 6 sellers · 12 mo
New fund stakes
2
Q2 2026 13F · 0 exits
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 2 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/6 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH Amylyx announced highly positive topline results from the Phase 3 LUCIDITY trial of avexitide in…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $51.3K at an average $13.51. 6 insiders sold $6.1M. Price is 101% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 21 added (2 new), 11 trimmed or exited. Largest new: Alyeska Investment Group, $18.9M, Aberdeen Group $13.2M.

  • AnalystsBULLISH

    16 of 18 rate it Buy or better. Median target $42.00 (+55%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.335 → −$0.372 over 90 days. 2 up, 4 down in 30 days.

  • Short sellersSTEADY

    Short interest −6.3% to 12.67M shares. 9.2 days to cover, ≈10.1% of shares.

  • TrendDOWNTREND

    13% below its 50-day average.

Who's buying

13F· Q2 2026
2
new positions
0
exits
$32.2M
in new stakes
FundMoveSharesValue
MORGAN STANLEYADD3,130,808$56.2M
JPMORGAN CHASE & CODOUBLED1,863,650$34.9M
ADAGE CAPITAL PARTNERS GP, L.L.C.TRIM1,900,000$34.1M
Alyeska Investment Group, L.P.NEW1,053,015$18.9M
BANK OF AMERICA CORP /DE/TRIM821,841$14.8M
Aberdeen Group plcNEW737,670$13.2M
BALYASNY ASSET MANAGEMENT L.P.TRIM684,974$12.3M
DEUTSCHE BANK AG\TRIM557,937$10.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 89% rate it Buy or better
Strong Buy9Buy7Hold2Sell0Strong Sell0
12-month targets · 11 analysts

Price is inside the target range. Median implies +55%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 15, 2026Citigroup
MAINTAIN
MAINTAINBuy
Aug 27, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 19, 2026Mizuho
MAINTAIN
MAINTAINOutperform
Aug 19, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 19, 2026Baird
MAINTAIN
MAINTAINOutperform
Aug 18, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$51.3K
bought · 1 insider
$6.1M
sold · 6 insiders
+100.6%
vs their $13.51 cost
DateInsiderTypeValue
Oct 5, 2026
MILNE GEORGE M JR
Director
SELL$830.9K
Sep 10, 2026
Bedrosian Camille L
Chief Medical Officer
SELL$68.9K
Sep 10, 2026
Bedrosian Camille L
Chief Medical Officer
SELL$256.0K
Sep 10, 2026
Cohen Joshua B
Co-Chief Executive Officer
SELL$950.0K
Sep 10, 2026
Mazzariello Gina
Chief Legal Officer
SELL$366.74
Sep 10, 2026
Klee Justin B.
Co-Chief Executive Officer
SELL$47.7K
Sep 10, 2026
Klee Justin B.
Co-Chief Executive Officer
SELL$932.6K
Sep 10, 2026
Cohen Joshua B
Co-Chief Executive Officer
SELL$30.5K

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.37
EPS estimate, this quarter
−11%
estimate change, 90 days
2↑ 4↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.37-$0.42–-$0.31+0.9%$41.6K
Next Q-$0.36-$0.41–-$0.24+0.7%-$41.6K
Current FY-$1.48-$1.60–-$1.26+0.9%$0.00
Next FY-$1.09-$1.63–$0.70+5.6%$28.3M

Short side

FINRA· Sep 30, 2026
12,666,971
shares short
-6.3%
vs prior settlement
9.2
days to cover
≈10.1%
of shares outstanding
Trading halts
Aug 18, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 5, 2026 SEC
Director George M. Milne Jr. filed a Form 144 notice of intent to sell 100,000 shares of Amylyx Pharmaceuticals…
144 — Impact 3/10
Oct 5, 2026 Insider
MILNE GEORGE M JR sold 30,000 shares
Director @ $27.70 ($830.9K)
Sep 14, 2026 SEC
Two C-suite insiders at Amylyx (CFO and CMO) sold a combined ~$103K in open-market sales on September 10, 2026, just…
CLUSTER — Impact 4/10
Sep 11, 2026 SEC
Two AMLX officers (James M. Frates and Camille L. Bedrosian) filed Form 144 notices on September 11, 2026, each…
144 — Impact 2/10
Sep 10, 2026 Insider
Bedrosian Camille L sold 2,081 shares
Chief Medical Officer @ $33.09 ($68.9K)
Sep 10, 2026 Insider
Bedrosian Camille L sold 7,947 shares
Chief Medical Officer @ $32.21 ($256.0K)
Aug 18, 2026 Trading halt
Halt Resumed: AMLX — trading resumed after T3 (News and Resumption Times)
Halted 2026-08-18T10:55:57.000Z | Resumed 2026-08-18T11:30:00.000Z
Jun 30, 2026 Inst.
MORGAN STANLEY — ADD
3,130,808 shares ($56.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
AMLX Q3 2026 Earnings Scheduled — 2026-11-05
Apr 13, 2027
FDA decision date
PDUFA: AMLX — avexitide in post-bariatric hypoglycemia — 2027-04-13
FDA target action date 2027-04-13 for AMLX (Amylyx Pharmaceuticals, Inc.). Drug: avexitide. Indication: post-bariatric hypoglycemia. PDUFA target…
Recent
Aug 18, 2026
Trading halt
Halt Resumed: AMLX — trading resumed after T3 (News and Resumption Times)
Halted 2026-08-18T10:55:57.000Z | Resumed 2026-08-18T11:30:00.000Z
Aug 18, 2026
Trading halt
Trading Halt: AMLX — T3 (News and Resumption Times)
Amylyx Pharmaceuticals, Inc. | Market: NASDAQ | Code: T3 — News and Resumption Times
Aug 18, 2026
Trading halt
Trading Halt: AMLX — T2 (News Released)
Amylyx Pharmaceuticals, Inc. | Market: NASDAQ | Code: T2 — News Released
Aug 18, 2026
Trading halt
Trading Halt: AMLX — T1 (News Pending)
Amylyx Pharmaceuticals, Inc. | Market: NASDAQ | Code: T1 — News Pending
Aug 6, 2026
Earnings date
AMLX Q2 2026 Earnings Scheduled — 2026-08-06

SecBot reports

10 filings · 2 bullish · 1 bearish · 1 mixed · 6 neutral
All AMLX filing & press-release reports (10)